Advertisement

Journal of Gastrointestinal Cancer

, Volume 50, Issue 1, pp 147–150 | Cite as

Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation

  • Ahmad Al-TaeeEmail author
  • Ammara Gill
  • Suzanne Mahon
  • Jinping Lai
  • Bassel Jallad
Case Report
  • 61 Downloads

Introduction

Gallbladder adenocarcinoma (GBAC) is an uncommon, but highly fatal malignancy that follows an aggressive course and complete remission is rare. Germline mutations in BRCA1 genes have been associated with a significantly increased risk of breast and ovarian cancers as well as other malignancies. Here, we describe the first case of gallbladder adenocarcinoma as the initial presentation of BRCA1 mutation.

Case Presentation

A 47-year-old Caucasian female presented to the clinic with a 2-month history of right upper quadrant abdominal pain and skin discoloration. Past medical history was remarkable for gastroesophageal reflux disease and aneurysmal bone cysts. She had a 20-pack year history of tobacco smoking but quit 15 years ago. Famotidine was the only home medication. Family history was unknown as the patient did not have contact with her parents.

Vital signs were unremarkable, and exam was notable for a thin female patient with a weight of 105 lb (48 kg), scleral icterus,...

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Patient Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

References

  1. 1.
    Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004;4(9):695–706.CrossRefGoogle Scholar
  2. 2.
    Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118(7):1591–602.CrossRefGoogle Scholar
  3. 3.
    Lazcano-Ponce EC, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51(6):349–64.CrossRefGoogle Scholar
  4. 4.
    Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist. 2010;15(2):168–81.CrossRefGoogle Scholar
  5. 5.
    Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94(18):1365–72.CrossRefGoogle Scholar
  6. 6.
    Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer. 1999;35(8):1248–57.CrossRefGoogle Scholar
  7. 7.
    Salo-Mullen EE, et al. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer. 2015;121(24):4382–8.CrossRefGoogle Scholar
  8. 8.
    Iqbal J, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2012;107(12):2005–9.CrossRefGoogle Scholar
  9. 9.
    Risch HA, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98(23):1694–706.CrossRefGoogle Scholar
  10. 10.
    C. Breast Cancer Linkage. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310–6.CrossRefGoogle Scholar
  11. 11.
    Sonnenblick A, et al. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther. 2011;12(3):165–8.CrossRefGoogle Scholar
  12. 12.
    Lohse I, et al. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Br J Cancer. 2015;113(3):425–32.CrossRefGoogle Scholar
  13. 13.
    Brown JS, Kaye SB, Yap TA. PARP inhibitors: the race is on. Br J Cancer. 2016;114(7):713–5.CrossRefGoogle Scholar
  14. 14.
    Xie Y, et al. Response of BRCA1-mutated gallbladder cancer to olaparib: a case report. World J Gastroenterol. 2016;22(46):10254–9.CrossRefGoogle Scholar
  15. 15.
    May T, Strong KA, Khoury MJ, Evans JP. Can targeted genetic testing offer useful health information to adoptees? Genet Med. 2015;17(7):533–5.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Department of Internal MedicineSaint Louis University School of MedicineSaint LouisUSA
  2. 2.Saint Louis University Cancer CenterSt LouisUSA
  3. 3.Department of PathologyUniversity of FloridaGainesvilleUSA

Personalised recommendations